Prader-Willi syndrome (PWS) is a genetic disorder caused by defi ciency of imprinted gene expression from the paternal chromosome 15q11-15q13 and clinically characterized by neonatal hypotonia, short stature, cognitive impairment, hypogonadism, hyperphagia, morbid obesity, and diabetes. Previous clinical studies suggest that a defect in energy metabolism may be involved in the pathogenesis of PWS. We focused our attention on the genes associated with energy metabolism and found that there were 95 and 66 mitochondrial genes differentially expressed in PWS muscle and brain, respectively. Assessment of enzyme activities of mitochondrial oxidative phosphorylation complexes in the brain, heart, liver, and muscle were assessed. We found the enzyme activities of the cardiac mitochondrial complexes II+III were up-regulated in the PWS imprinting center deletion mice compared to the wild-type littermates. These studies suggest that differential gene expression, especially of the mitochondrial genes may contribute to the pathophysiology of PWS.
Introduction
Prader-Willi syndrome (PWS) is a complex neurodevelopmental disorder resulting from defi ciency of imprinted gene expression from paternal chromosome 15q11-15q13.
1,2 PWS is characterized by multiple clinical manifestations during development and adulthood. In utero features include reduced fetal movement and polyhydramnios and in infancy, feeding difficulties, hypogonadism, hypotonia, and failure to thrive. During childhood, delayed motor speech development, behavioral abnormalities that include hyperphagia, and sleep disorder predominates. During adolescence, obesity, short stature, and delayed puberty are observed, and in adulthood, infertility, hypogonadism, cognitive impairment, and morbid obesity are significant problems. Dysmorphic features include bitemporal narrowing, upslanting palpebral fi ssures, and small hands and feet. 3 The chromosome 15q11-q13 region contains imprinted sequences that are diff erentially expressed depending on the parent of origin. Due to imprinting, the maternally inherited copies of these genes are virtually silent, with only the paternal copies of the genes being expressed. In 70% of individuals, PWS results from the absence of paternally expressed imprinted genes located on chromosome 15q11-q13, including SNRPN , NECDIN , MAGEL2 , and MKRN3 genes along with clusters of snoRNAs: SNORD64 , SNORD107 , SNORD108 , two copies of SNORD109 , 29 copies of SNORD116 (HBII-85), and 48 copies of SNORD115 (HBII-52). 4, 5 Maternal uniparental disomy (UPD) in which there are two maternal and no paternal copies of this region accounts for 30% of PWS cases. Deletion of the same region on the maternal chromosome causes Angelman syndrome. An imprinting center (IC) in cis regulates the establishment of parental specifi c allelic differences in DNA methylation, chromatin structure, and expression of genes in the PWS critical region. Although the 15q11-q13 defect underlies the PWS phenotype, the genes within the region do not appear to be directly responsible for the complex phenotype. Rather, it seems likely that the PWS phenotype results from dysregulation of multiple interconnected neurological and metabolic pathways. 6 Th e PWS critical region extends over nearly half of 15q11-q13 and contains multiple paternally expressed genes. Th e protein-coding genes, small nuclear ribonucleoprotein N (SNRPN), and its bicistronic partner SNRPN upstream reading frame (SNURF) have been mapped to the PWS critical region. 7, 8 Families with microdeletions causing PWS localize the PWS-IC to 4.3 kb overlapping with SNRPN exon 1.
9 SNURF and SNRPN are paternally expressed and encode two diff erent proteins within a single transcript. 6 SNRPN/SNURF-SNRPN exon1 is embedded in a CpG island with complete methylation on the maternal allele and complete absence of methylation on the paternal allele. Recent fi ndings have shown that deletion of the 29 copies of the C/D box snoRNA SNORD116 (HBII-85) appears to be the primary cause of PWS. 10 Th e PWS-IC mouse model is a powerful tool that can be effi ciently used to better understand the biochemical and cellular mechanisms involved in human PWS. Th ere are now considerable insights from various deletions and other mutations in essential regulatory elements, such as the IC and one or more paternally expressed structural genes in the PWS domain that these loci are important in generating the PWS phenotype. Maternal UPD/ paternal defi ciency produce neonatal lethality in 100% of mice. 11 Similarly, a large deletion associated with a transgenic insertion caused lethality in 100% of the mice with paternal inheritance. 12 A 35-kb deletion of the putative IC causes complete lethality and an imprinting defect when inherited from male chimeras. Deletion of this IC abolishes local paternally derived gene expression and 3, 7 , and Virginia E. Kimonis , M.D., M.R.C.P. results in PWS. 13 Both the position of the IC and its role in the coordinate expression of genes is conserved between mouse and human, therefore indicating that the mouse is a suitable model system in which to investigate the molecular function and pathophysiological implication of imprinting defects. A complete imprinting defect (UPD and the 35-kb deletion of the mouse IC) causes complete or severe lethality, whereas a partial imprinting defect (the 4.8-kb deletion of the Snrpn promoter) causes partial or lesser lethality.
14 Lack of Pwcr1/MBII-85 snoRNA is critical for neonatal lethality in PWS mouse model. 15 Another deletion introduced into the germline using homologous recombination removed the coding exons for both Snurf and SmN and for Ube3a and removed all of the intervening 0.5-0.7 Mb of genomic DNA. Th is deletion from Snrpn to Ube3a on the paternal chromosome is associated with severe growth retardation, hypotonia, and approximately 80% lethality and position eff ects on expression of imprinted genes. Th e surviving mice with the Snrpn-Ube3a deletion were fertile and were not obese. 16 In all cases of lethality in the PWS mouse models, the abnormal phenotype occurs only with paternal defi ciency and is associated with decreased movement and poor feeding immediately aft er birth.
Previous work involving whole genome microarrays using RNA isolated from lymphoblastoid cells from PWS patients has revealed signifi cant diff erences in expression patterns of numerous genes related to normal neurodevelopment and function including serotonin receptor genes (e.g., HTR2B ); genes involved in eating behavior and obesity ( ADIPOR2 , MC2R , HCRT , OXTR ); STAR (a key regulator of steroid synthesis); and SAG (an arrestin family member which desensitizes G-protein-coupled receptors). 17 In addition, the same group also performed whole genome microarrays on a PWS-IC deletion (PWS-IC del) mouse model on RNA extracted from whole brain tissue within 24 hours aft er birth. Th eir results demonstrated two very signifi cant diff erences: fi rst, an increased expression of Pomc and Mc5r , the former of which is believed to be involved in eating behavior and the latter in thermoregulation; and second, decreased expression of three relatively uncharacterized transcripts that are expressed from the paternal allele under regulatory control of the IC (AK013560, BB3144814, BB182944). 17 Mitochondria, in addition to playing perhaps the most prominent role of all organelles in energy metabolism, are central to many cellular functions including the generation of ATP, intracellular Ca2+ homeostasis, reactive oxygen species (ROS) biology, and apoptosis. 18 Mitochondria are one of the most abundant organelles in muscle and brain cells, responsible for producing the majority of energy through oxidative phosphorylation (OXPHOS). Many genes associated with neurodegenerative diseases are now known to regulate mitochondrial function. 19 Mitochondrial dysfunction has been implicated in Parkinson's disease, 20 Huntington's disease, 21 amyotrophic lateral sclerosis, 22 muscular dystrophy, 23 type 2 diabetes mellitus, 24 and collagen VI myopathies. 25 Despite a lack of clinical or animal studies demonstrating effi cacy, a high percentage of patients with PWS are being treated with co-enzyme Q10 (Co-Q10). A vitamin-like substance, Co-Q10 is present in most eukaryotic cells, primarily in the mitochondria where it is a component of the electron transport chain functioning as an electron acceptor from complexes I and II before passing on the electron to complex III. Unpublished data from our laboratory indicates that of the majority of patients on Co-Q10 derive some benefi t mainly with regard to their energy level. To date, no double-blind study has been undertaken to study the eff ects of Co-Q10 on mitochondrial activity.
Given that previous fi ndings have demonstrated diff erentially expressed genes involved in energy metabolism; that patients derive therapeutic benefi t from supplementation with a mitochondrial component of the electron transport chain; the abundance of mitochondria in neuronal, liver, and skeletal muscle tissues; and that mitochondria play a central role in energy metabolism through ATP generation and pathophysiologic manifestations through ROS generation, we hypothesized that mitochondrial dysfunction is a pivotal component of PWS pathology.
We investigated the gene expression profi les of the quadriceps muscle and brain tissues in PWS-IC transgenic mouse model. Using RNA isolated from these tissues, we performed a comprehensive analysis of diff erential gene expression using the microarray approach with a goal to identify altered genes and link them to specifi c pathways that are relevant to PWS.
Methods

PWS-IC del mouse model
PWS-IC del mice were developed as described previously 26 and were kindly provided by Dr. Resnick (College of Medicine, University of Florida, Gainesville, FL, USA). All experiments were done with the approval of the Institutional Animal Care and Use Committee (IACUC Protocol #2007-2716-1) of the University of California, Irvine (UCI), and in accordance with the guidelines established by the NIH. All animals were housed in the vivarium of the UCI and maintained under constant temperature (22°C) and humidity with a controlled 12:12-hour light-dark cycle. PWS-IC del mice weighed approximately 16-20 g and wild-type (WT) littermates weighed approximately 30-35 g. All animals were 6 months old females and an F1 hybrid of WT friend leukemia virus B strain (FVB) females and B6 males bearing the 35-kb IC del mutation strains. Mutant mice were bred aft er culling all but one WT pup within a day of birth. So, the animals were presumed to have FVB mitochondria.
Electron microscopy
Mutant and WT mice tissues were fi xed in 4% paraformaldehyde plus 0.1% glutaraldehyde in 0.1 M PB for 24 hours. Sections (100 μ M) were cut with a vibratom, then collected in PBS and fi xed in 1% glutaraldehyde overnight. Tissue samples were fi xed in 1% osmium for 1 hour at 4°C and dehydrated in ethanol, which are embedded in eponate 12 resin at 65°C for 24-36 hours. Ultrathin (approximately 60-80 nm) sections were cut with a diamond knife and stained in 1% uranyl acetate for 30 minutes, followed by lead citrate for 7-10 minutes. Electron micrographs (EMs) were taken with a Gatan UltraScan US1000 digital camera and examined on a Philips CM10 transmission electron microscope.
Mitochondrial isolation and OXPHOS enzyme analysis
Mitochondria were isolated from the liver, heart, skeletal muscle (vastus lateralis), and the whole brain by homogenization and diff erential centrifugation as described previously. 27 Mitochondrial enzyme complex activities were determined by OXPHOS enzyme assays using our standard protocols. 6 In brief, equal amounts of mitochondrial proteins were assayed and normalized to citrate synthase (CS) activity, which remained at unchanged levels throughout the assay.
Complex I activity assay
A total of 80 μ L of water, 100 μ L of 2× buff er (500 mM sucrose, 2 mM EDTA, 100 mM Tris-HCl at pH 7.4), 2 μ L of 10 mM decylubiquinone (Sigma-Aldrich, St. Louis, MO, USA), 0.5 μ L of 2 M KCN, and 10 μ L of 1 mg/mL mitochondria incubated for 5 minutes at 30°C. Th e reaction was started by adding 10 μ L of 1 mM NADH, aft er which absorbance was measured at 340 nm for 5 minutes to quantify the rotenone-sensitive activity, which was determined in the presence of 1 μ L of 1 mg/mL rotenone in a parallel experiment.
Complex II+III activity assay
Th e rate of cytochrome c (cytc) reduction was measured at 550 nm in a reaction containing 110 μ L of water, 80 μ L of 100 mM potassium phosphate buff er (pH 7.4), 4 μ L of 1 M succinate, 1 μ L of 0.1 M EDTA, 0.5 μ L of 2M KCN, and 6 μ L of 1 mM cytc. Note that, 5 μ L of 1 mg/mL mitochondria was added and the absorption was monitored at 550 nm for 2 minutes.
Complex IV oxidation assay
Th e rate of cytc oxidation was measured at 550 nm in a reaction containing 170 μ L of water, 20 μ L of 100 mM potassium phosphate buff er (pH 7.4), and 10 μ L of 1 mM reduced cytc. Note that, 5 μ L of 0.1 mg/mL mitochondria was added. Th e absorption at 550 nm was monitored for 2 minutes. Reduced cytc was prepared by adding 2 μ L of 1 M dithiothreitol to 1 mL of 1 mM cytc and incubated for 15 minutes.
CS activity assay
Th e reduction of 5,5′-dithio-bis (2-nitrobenzoic acid; DTNB) was measured at 412 nm in a reaction containing 160 μ L of water, 20 μ L of 1 M Tris-HCl (pH 8.0), 10 μ L of 6 mM acetyl-CoA, and 2 μ L of 10 mM DTNB by adding 5 μ L of 1 mg/mL mitochondria. Th e absorption at 412 nm was monitored for 2 minutes.
Mitochondrial enzyme analysis
Measurements of mitochondrial enzyme activities were repeated three times for each test on each animal. Th e unpaired student's t -test was used to evaluate diff erences in WT and mutant values. Data represent mean ± SD. An analysis with a value of p < 0.05 was considered to be statistically signifi cant.
Microarray analysis
Skeletal (quadriceps) and whole brain samples from the mutant mice ( n = 3) and their WT age-matched littermates ( n = 4) were analyzed by microarray technology using the Mouse Genome 430 2.0 arrays (Aff ymetrix, Santa Clara, CA, USA). Total RNA was extracted using a TRIzol-reagent (Invitrogen) and purifi ed with RNeasy Mini kit (Qiagen , Valencia, CA, USA). RNA concentration was determined by spectrophotometry (Bio-Rad, Hercules, CA, USA) and the quality of RNA samples was assessed by Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA). Note that, 2 μ g of total high-quality RNA was used to start cDNA-cRNA synthesis by in vitro transcription using Aff ymetrix GeneChip® Expression 3′Amplifi cation One-Cycle Target Labeling and Control Reagent kit. Double-stranded cDNA and Biotinylated cRNA were purifi ed by Gene Chip Sample Cleanup Module (Aff ymetrix). Note that, 17 μ g of biotinylated cRNAs from samples are fragmented, 15 μ g of which were placed in a hybridization mixture of which 10 μ g was hybridized to
an Aff ymetrix Gene-Chips array for 16 hours. Th e arrays were washed and stained on the Aff ymetrix Fluidics Station 450 (Aff ymetrix) according to manufacturer's instructions. Briefl y, nonspecifi cally bound material was removed and followed by incubation with phycoerythrin-streptavidin to detect bound cRNA. Th e signal intensity was amplifi ed by second staining with biotin-labeled antistreptavidin antibody followed by phycoerythrin-streptavidin restaining. Fluorescent images were captured using the Aff ymetrix Gene Chip Scanner 3000 7G.
Gene expression profi ling data analysis
Cell intensity fi le (CEL) image fi les were analyzed with the Probe Logarithmic Intensity Error algorithm (PLIER; Aff ymetrix). Unsupervised clustering of the data from all samples was performed with Hierarchical Clustering Explorer (HCE) 3. Th e PLIER data set was also analyzed with the data-mining program GeneSpring GX (version 7.3.1; Agilent Technologies, Inc.). Before screening for probe sets with altered expression levels, the data set, or signal intensities were normalized in two ways: (1) to each chip using a distribution of all genes around the 50th percentile; (2) to the mean values of infected sample's own control, so that all probe sets from control samples had a mean value of 1, and probe sets from mutant versus control samples had a value of either greater than, less than, or equal to 1, representing up-regulation, down-regulation, or no change, respectively. Only probe sets that were statistically signifi cant via one-way ANOVA t -test with a p -value cutoff of p < 0.001 or p < 0.01 were considered further. Data were clustered as gene trees where yellow represents an expression ratio around 1, or no change (controls), and hotter colors (red = maximum) indicate an increase, and cooler colors (blue = minimum) indicate a decrease from control levels. For the generation of canonical pathways and networks, we used Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Redwood City, CA, USA). Th e hyperlink of the GEO submission for study number GSE41759 is: http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE41759 .
Quantitative real-time PCR (qRT-PCR)
Expression levels of genes that are most significantly diff erentially expressed (at least >1.5-fold diff erence) between control and mutant samples were confi rmed by qRT-PCR using Roche LightCycler 480 Real-Time PCR System (Roche Applied Science, Indianapolis, IN, USA). Note that, 200 ng of total RNA were treated with DNAse I (Roche Diagnostics) before cDNA synthesis that was prepared using transcription kit and random hexamers (Applied Biosystems, Carlsbad, CA, USA). RT reactions were carried out in 20 μ L according to manufacturer's protocol, and 1.8 μ L of cDNA was used for each qRT-PCR reaction. In order to validate our microarray data, predesigned fl uorogenic 6-carboxyfl uorescein (FAM)-labeled primers/probes were used to measure transcription levels of the selected genes. Probes for the qRT-PCR validation were selected from Applied Biosystems Web site, and were used as sense/antisense primers. For the muscle tissue the following assays were used: Actc1 (ID: Mm00477277_g), Igfb pl1 (ID: Mm00497621_m1), Casr (ID: Mm00443375_m1), Mppe1 (ID: Mm00553989_m1), Tbc1d1 (ID: Mm00497989_m1); and for the brain tissue we used: Mrpl15 (ID: Mm00804108_m1) and Utrn (ID: Mm01168866_m1). Mouse GAPDH (Part Number 4352932E) was used as an endogenous control. All qRT-PCR results were normalized to control samples.
Results
Diff erentially expressed transcripts in the PWS-IC del mice and analysis of ingenuity networks
We analyzed gene expression from the skeletal muscle and brain tissues of the PWS-IC del mice by using whole genome microarray.
Gene-clustering analysis of statistically signifi cant ( p < 0.01), diff erentially expressed genes revealed dysregulated expression of 726 genes in muscle and 332 genes in brain of PWS-IC mice as compared to littermate controls ( Figure 1 ). We then grouped the genes that had a signifi cant change in expression using IPA software (Ingenuity Systems) into biofunctional pathways for muscle and brain ( Figure 2 and Table 1 ). Statistically signifi cant genes with the greatest fold change found in both muscle and brain are listed in Table 2 . Of the differentially expressed genes, we found 95 and 66 mitochondrial genes diff erentially expressed in PWS-IC muscle and brain, respectively, at p < 0.05 ( Table 3 ) . As predicted, all the known genes from the PWS critical region were down-regulated and Ube3a was signifi cantly up-regulated. Previous microarray fi ndings using a day old PWS mice 17 of which up-regulation of Mc5r (melanocortin receptor) and its interaction partner pro-opiomelanocortin (Pomc) were not observed. In order to validate our microarray data, we further investigated two significant genes in PWS muscle by RT-PCR. We confi rmed that actin α cardiac muscle1 (Actc1) was up-regulated and Tre-2/Bub2/Cdc16 (TBC) domain family, member1 (Tbc1d1) was down-regulated in the PWS-IC del mice relative to their control littermates ( Figure 3 ).
Analysis of mitochondrial complexes
To assess mitochondrial bioenergetic function, we assayed the relative activity of complexes I, II+III, and IV in skeletal muscle, liver, heart, and brain tissues of PWS-IC mice compared to their littermate controls. Th e data were normalized by CS activities. Reproductive system development and function 3.29E-04-4.40E-02 4
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Hematological system development and function 1.50E-04-4.40E-02 8
Immune cell traffi cking 1.50E-03-5.00E-02 4 Th e relative activities of mitochondrial complexes II+III were signifi cantly up-regulated in cardiac muscle in PWS-IC del mice when compared to WT mice (student t-test, p < 0.01). Normalized complexes I, II+III, and IV activities in the brain, liver, and skeletal muscles were not signifi cantly diff erent between the PWS-IC del and WT mice ( Figure 4 ).
Mitochondrial EM structural changes
EM studies on cardiac and skeletal muscle tissues were reviewed in PWS-IC deletion mice compared to their WT littermate controls. We found abnormal mitochondrial proliferation, disorganized mitochondria swollen in appearance with disrupted membranes in both cardiac and skeletal muscle in PWS-IC del mouse as compared to littermate controls ( Figure 5 ).
Discussion
PWS results from a loss of paternal imprinted genes from chromosome 15q11-15q13, leading to a profound disturbance of neurodevelopment that manifests multiple complex phenotypes including ones involved in energy metabolism, behavioral, cognitive, and structural defects. Complexes I, II+III, and IV activities in the brain, liver, heart, and skeletal muscles from PWS-IC and WT mice. The normalized complexes I and IV activities in the brain, liver, heart, and skeletal muscles and complexes II+III activities in the brain, liver, and skeletal muscles were not signifi cantly different between the PWS-IC deletion and WT mice normalized to citrate synthase activity, which remained unchanged.
the downstream-aff ected genes are involved in various energy metabolism pathways. 17 In addition, clinical evidence has shown a role for Co-Q10 supplementation in patient improvement. Th us far, to the best of our knowledge, no one had studied the possible role of mitochondrial dysfunction in PWS, we hypothesize that a component of PWS pathology is related to mitochondrial function.
We then conducted genome microarray analysis of RNA transcripts in skeletal muscle and brain tissues of our PWS-IC deletion mice, specifi cally looking for altered expression of genes involved in various mitochondrial pathways. We found 95 and 66 mitochondrial genes diff erentially expressed in WT and PWS-IC muscle and brain. As expected, all the known genes from the PWS critical region were down-regulated and Ube3a was signifi cantly up-regulated.
Focusing our attention on transcripts that demonstrated a fold change (FC) of greater than 1.5 or less than -1.5, we discovered several mitochondrial genes that fall under cellular metabolism pathways by Ingenuity networks analysis. Specifi cally, in brain tissues Mrpl15 (mitochondrial ribosomal protein L15) was up-regulated, while Alas1 (aminolevulinic acid synthase 1) was down-regulated. Mrpl15 encodes a 39s subunit protein that make up a part of the mitochondrial ribosome required for mitochondrial protein synthesis. 28 Recent bioinformatics approaches have linked this gene to possibly playing a role in stem cell pluripotency and diff erentiation. 29 Alas1 gene product is a nuclear-encoded mitochondrial enzyme that is the ratelimiting and fi rst enzyme in the heme biosynthetic pathway. A recent study has found down-regulated levels of this enzyme in Alzheimer's disease, possibly suggesting that down-regulated levels of this enzyme and dysfunctional heme metabolism could play a role in the cognitive and behavioral abnormalities seen in PWS.
In muscle tissues, we discovered the following downregulated nuclear-coded mitochondrial gene expression levels; Bdh (3-hydroxybutyrate dehydrogenase) involved in fatty acid catabolism, Mte1 (mitochondrial acyl-CoA thioesterase 1), involved in lipid metabolism pointing to a possible underlying mitochondrial role in biochemical metabolism pathways in PWS pathophysiology. Acadl (acetyl-Coenzyme A dehydrogenase, long-chain) belongs to the acyl-CoA dehydrogenase family of mitochondrial fl avoenzymes involved in fatty acid and branched chain amino acid metabolism. Th e resulting protein is one of the four enzymes that catalyze the initial step of mitochondrial beta-oxidation of straight-chain fatty acid. Defects in this gene are the cause of long-chain acyl-CoA dehydrogenase defi ciency, leading to nonketotic hypoglycemia [provided by RefSeq]. Finally, variants of Mtch2 (mitochondrial carrier homolog 2) in humans have demonstrated a link with obesity 30 providing yet another potential clue to the role of mitochondrial dysfunction in the pathophysiology of PWS.
We have observed in a PWS-IC mouse model changes in muscle and brain mitochondrial gene expression and mitochondrial proliferation. We found signifi cant structural changes on EM in cardiac cells of our PWS-IC del mouse model in addition to an increase of complex II+III activity in cardiac tissues.
Th ese observations are consistent with previous reports of diff erential expression of energy metabolism genes and provide an explanation for possible therapeutic benefi t from Co-Q10 supplementation. Co-Q10 plays a pivotal role as an electron acceptor from complex II before passing on those electrons to complex III. Th is study provides support for our hypothesis that PWS patients have an underlying defect in mitochondrial bioenergetics that is partially compensated by the up-regulation of mitochondrial biogenesis.
Conclusion
In conclusion, we have demonstrated ultra structural, enzymatic, and transcriptional changes of key mitochondrial components that point to a substantial role of mitochondrial dysfunction in the pathophysiology of PWS in the PWS-IC model. In addition, our microarray fi ndings have detected previously unknown candidate genes that need to be studied in more detail to fully elucidate their potential role in PWS. In conclusion, this current work supports the rationale for Co-Q10 supplementation in PWS in alleviating some of the symptoms associated with this disease. Such studies could lead to other possible novel therapeutic avenues in treating this disease. 
